At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 631 enrolled
Drug / intervention
Ruxolitinib Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Ruxolitinib Cream and Vehicle Cream for Atopic Dermatitis. Completed, enrolled 631 participants across 79 sites in 7 countries.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, France, Germany, Hungary, Italy, Poland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartDec 2018
Primary CompletionDec 2019
Study CompletionDec 2020
TodayJul 2026
First PostedNov 19, 2018
Enrollment StartDec 20, 2018
Primary CompletionDec 23, 2019
Study CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.6 years ago
Interventions
Ruxolitinib Creamdrug
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Vehicle Creamdrug
Matching vehicle cream applied topically to the affected area as a thin film twice daily.